Lercanidipine, a vital calcium channel blocker used to treat hypertension, relies on a sophisticated chemical synthesis pathway. At the heart of this process is the intermediate 2,N-Dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol, bearing the CAS number 100442-33-9. Its precise molecular structure (C20H27NO) and properties are fundamental to achieving the desired pharmaceutical outcome.

NINGBO INNO PHARMCHEM CO.,LTD. specializes in producing high-purity intermediates like 2,N-Dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol, understanding that the quality of the intermediate directly impacts the efficacy and safety of the final drug. The compound, typically appearing as a pale yellow liquid, has a molecular weight of 297.43 g/mol. Manufacturers involved in the purchase of this chemical often scrutinize its price, purity levels, and the reliability of its supply chain. The ability to buy in bulk is also a significant consideration for large-scale production.

The synthesis of Lercanidipine involves multiple steps, where 2,N-Dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol acts as a key building block, facilitating the formation of the complex final molecule. Understanding the chemical synthesis of this intermediate itself is crucial for optimizing its production and ensuring cost-effectiveness. NINGBO INNO PHARMCHEM CO.,LTD. employs advanced organic chemistry techniques to guarantee the consistent quality and availability of this vital component. The reliable availability of such intermediates is essential for maintaining the global supply of critical medications.

As a dedicated supplier of pharmaceutical intermediates, NINGBO INNO PHARMCHEM CO.,LTD. plays a crucial role in the pharmaceutical ecosystem. By providing high-quality 2,N-Dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol, we empower pharmaceutical companies to develop and manufacture life-changing treatments. Our commitment to excellence in chemical synthesis ensures that our partners can rely on us for their critical raw material needs, thereby contributing to better patient outcomes worldwide.